Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239

Benzinga Newsdesk www.benzinga.com Positive 78.0%

Neg 0% Neu 0% Pos 78%

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.